ZIVO vs. BTMD, INBX, DSGN, ESPR, NBTX, MDWD, CRDF, IMAB, PRQR, and SOPH
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include biote (BTMD), Inhibrx Biosciences (INBX), Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Nanobiotix (NBTX), MediWound (MDWD), Cardiff Oncology (CRDF), I-Mab (IMAB), ProQR Therapeutics (PRQR), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs. Its Competitors
biote (NASDAQ:BTMD) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.
biote has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
biote has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.
biote presently has a consensus target price of $8.00, indicating a potential upside of 94.17%. Given biote's stronger consensus rating and higher possible upside, equities analysts plainly believe biote is more favorable than ZIVO Bioscience.
21.7% of biote shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 24.0% of biote shares are owned by insiders. Comparatively, 21.5% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
biote has a net margin of 10.93% compared to ZIVO Bioscience's net margin of 0.00%. ZIVO Bioscience's return on equity of 0.00% beat biote's return on equity.
In the previous week, biote and biote both had 1 articles in the media. biote's average media sentiment score of 1.89 beat ZIVO Bioscience's score of 0.75 indicating that biote is being referred to more favorably in the media.
Summary
biote beats ZIVO Bioscience on 13 of the 15 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 7/1/2025 by MarketBeat.com Staff
Free ZIVO Stock Alerts